Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib + Chemotherapy + Cetuximab β in Advanced Pancreatic Cancer
NCT07302841Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of tunlametinib in pancreatic cancer (PC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 2 years. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tunlametinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07302841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07302841.